ImmunityBio Inc. (IBRX)
3.02
-0.12 (-3.82%)
At close: Mar 31, 2025, 3:22 PM
ImmunityBio Inc. Revenue Breakdown
Quarter | Sep 30, 2024 |
---|---|
Product and Service, Other Revenue | 152K |
Product and Service, Other Revenue Growth | n/a |
Product Revenue | 5.95M |
Product Revenue Growth | n/a |
Revenue by Geography
Quarter | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 |
---|---|---|---|---|---|---|
Europe Revenue | 591K | 198K | 561K | n/a | n/a | 21K |
Europe Revenue Growth | +198.48% | -64.71% | n/a | n/a | -100.00% | n/a |
United States Revenue | 31K | 42K | 373K | 45K | 44K | n/a |
United States Revenue Growth | -26.19% | -88.74% | +728.89% | +2.27% | n/a | n/a |
Operating Expense Breakdown
Quarter | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selling, General, and Administrative Revenue | 35.92M | 49.25M | 37.83M | 29.05M | 31.82M | 32.02M | 32.68M | 26.21M | 19.31M | 16.57M | 40.61M | 27.91M | 29.63M | 32.45M | 45.27M | 23.88M | 19.6M | 18.35M | 9.49M | 8.53M | 4.03M | 4.18M | 5.74M | 5.25M | 9.58M | 13.59M | 14.3M | 13.38M | 13.38M | 14.13M | 16.23M | 15.71M | 24.42M | 28.59M | 26.65M | 74.83M | 38.85M | 82.43M |
Selling, General, and Administrative Revenue Growth | -27.08% | +30.19% | +30.24% | -8.71% | -0.63% | -2.01% | +24.65% | +35.76% | +16.50% | -59.18% | +45.49% | -5.79% | -8.69% | -28.34% | +89.58% | +21.87% | +6.81% | +93.27% | +11.34% | +111.83% | -3.75% | -27.17% | +9.45% | -45.24% | -29.53% | -4.92% | +6.82% | +0.03% | -5.29% | -12.94% | +3.27% | -35.66% | -14.57% | +7.27% | -64.39% | +92.60% | -52.86% | n/a |
Research and Development Revenue | 50.44M | 51.13M | 52.85M | 51.03M | 48.4M | 53.17M | 79.26M | 58.08M | 71.61M | 63.08M | 55.38M | 51.75M | 49.28M | 53.8M | 41.13M | 43.36M | 35.77M | 33.01M | 27.37M | 13.19M | 12.05M | 13.13M | 12.6M | 12.48M | 14.56M | 14.69M | 13.99M | 12.02M | 11.07M | 9.71M | 9.25M | 9.45M | 8.36M | 6.39M | 4.94M | 5.11M | 3.95M | 1.75M |
Research and Development Revenue Growth | -1.34% | -3.26% | +3.56% | +5.43% | -8.96% | -32.92% | +36.48% | -18.90% | +13.52% | +13.91% | +7.00% | +5.02% | -8.41% | +30.81% | -5.14% | +21.20% | +8.38% | +20.57% | +107.49% | +9.47% | -8.22% | +4.23% | +0.95% | -14.28% | -0.88% | +4.98% | +16.39% | +8.60% | +14.04% | +4.95% | -2.09% | +12.92% | +30.91% | +29.23% | -3.17% | +29.27% | +126.36% | n/a |